In September 2021, we hosted our International Research Workshop virtually, and in conjunction with our Together We Will Virtual Weekend. Over ~170 physicians and researchers signed up for the 2021 Research Workshop, expanding our worldwide participation to ~100 institutions from 30 countries.
Agenda
Welcome
Jeanne Whiting
President and Co-Founder, DTRF
Welcome/DTRF Updates
Benjamin Alman, MD
Professor & Chair, Orthopaedic Surgery, Duke University
Maneesh Kumar, MD, PhD
Research Director, DTRF Coordinating Center
Diagnostic and therapeutic strategies for extra-abdominal desmoid-type fibromatosis: a longitudinal questionnaire survey to specialized centers in Japan.
Yoshihiro Nishida, MD
Rehabilitation & Orthopedic Oncology, Nagoya University Graduate School of Medicine
Genomic and transcriptomic analysis of desmoid tumor reveals enrichment of transforming growth factor beta responsive signature.
Hyo Song Kim, MD
Department of Internal Medicine, Yonsei University
Evaluation of the Cryodestruction of Non- Abdominopelvic Desmoid Tumors in Patients Progressing despite Medical Treatment (CRYODESMO01).
Afshin Gangi, MD, PhD
Strasbourg’s University Hospitals
Prognosis value of S45F mutation of CTNNB1 in desmoid-type fibromatosis (DF). Prospective analysis of 500 consecutive patients (pts) from ALTITUDES Trial.
Nicholas Penel, MD, PhD
Director of Clinical Research & Innovation Dept/ Head of General Oncology in Medical Oncology, Oscar Lambret Cancer Centre
Abdominal Desmoid Tumors: A series from a single institution.
Sara Coppola, MD
Sarcoma Department, IEO Istituto Europeo di Oncologia
Data sharing and RDCA-DAP.
Ed Neilan, MD, PhD
Chief Medical Officer, NORD
KEYNOTE: Not all anti-tumor T cell responses are created equal.
Stefani Spranger, PhD
Assistant Professor of Biology, Massachusetts Institute of Technology
Investigating the mechanisms and tumor-host interactions mediating desmoid tumor regression by EZH2 inhibition in CRISPR-based Xenopus tropicalis models.
Kris Vleminckx, PhD
Professor of Developmental Biology, Ghent University
Evaluating CD47 blockade as a potential immunotherapy for desmoid-type fibromatosis.
Gerlinde Wernig, MD
Assistant Professor, and Cristabelle De Souza, MD, Postdoctoral Fellow, Department of Pathology, Stanford University
Developing a physiologically relevant target validation platform for desmoid tumors.
Mushriq Al-Jazrawe, PhD
Post-doctoral Associate, The Broad Institute of MIT and Harvard
CRISPR/Cas9 approach for creating a simplified cellular model to study the Desmoid cells in response to external stimuli and in cellular communication.
Daniela Segat, PhD
Researcher, “Mauro Baschirotto” Institute for Rare Diseases – BIRD Foundation
Circulating tumor cells in desmoid tumors.
Ludmilla Thome Domingos Chinen, PhD
Senior researcher, Pesquisadora Hospital ACCamargo- Fundação Antônio Prudente
Patient-reported outcomes in patients with desmoid type fibromatosis.
Sameer Rastogi, MD
Associate Professor, Dept. of Medical Oncology, All India Institute of Medical Sciences (AIIMS), New Delhi
Intestinal transplant as rescue therapy.
Sukanya Subramanian, MD
Transplant Gastroenterologist, Medstar Georgetown University Hospital
An Update on the Phase 3 DeFi Trial Evaluating Nirogacestat in Adult Patients with Progressing Desmoid Tumors.
Ana Oton, MD
VP of Medical Affairs, Nirogacestat Program, SpringWorks Therapeutics
Amanda Hoffman
Desmoid Patient Advocate
AL102, Investigational Oral Gamma-Secretase Inhibitor for the Potential Treatment of Desmoid Tumors.
Gary Gordon, MD, PhD
Chief Medical Officer, and Jason Kaplan, MD, Medical Director, Ayala Pharmaceuticals
The Epidemiology of Desmoid Tumors in Denmark.
Jessica White, PhD student
SpringWorks Therapeutics, Inc.
DTRF’s Natural History Study- Sept 2021 Update.
Kelly Mercier, PhD
Principal Investigator, DTRF Patient Registry & Chair, DTRF Coordinating Center
Role of Multidisciplinary Care in Complex Desmoids.
Rebecca Gladdy, MD, PhD
Associate Professor, General surgery, University of Toronto
The International Pregnancy Study.
Chandrajit Raut, MD, MSc
Professor of Surgery, Harvard Medical School Chief, Division of Surgical Oncology, Department of Surgery, Brigham and Women’s Hospital Surgery Director, Center for Sarcoma and Bone Oncology, Dana-Farber Cancer Institute